Menactra Label Does Not Allow For Comparative Claims, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for Sanofi-Aventis' Menactra does not allow for superiority claims, FDA said in its Jan. 14 approval letter for the meningococcal conjugate vaccine